Diabetic Kidney Disease Alters The Transcriptome And Function Of Human Adipose-Derived Mesenchymal Stromal Cells But Maintains Immunomodulatory And Paracrine Activities Important For Renal Repair

LaTonya J Hickson,Alfonso Eirin,Sabena M Conley,Timucin Taner,Xiaohui Bian,Ahmed Saad MBBCh,Sandra M Herrmann,Ramila A Mehta,Travis J McKenzie,Todd A Kellogg,James L Kirkland,Tamar Tchkonia,Ishran M Saadiq,Hui Tang,Kyra L Jordan,Xiangyang Zhu,Mathew D Griffin MBBCh,Andrew D Rule,Andre J van Wijnen,Stephen C Textor,Lilach O Lerman

DOI: https://doi.org/10.2337/db19-1268

IF: 7.7

2021-01-01

Diabetes

Abstract:Mesenchymal stem/stromal cells (MSCs) facilitate repair in experimental diabetic kidney disease (DKD). However, the hyperglycemic and uremic milieu may diminish regenerative capacity of patient-derived therapy. We hypothesized that DKD reduces human MSC paracrine function. Adipose-derived MSC from 38 participants with DKD and 16 control subjects were assessed for cell surface markers, trilineage differentiation, RNA sequencing (RNA-seq), in vitro function (coculture or conditioned medium experiments with T cells and human kidney cells [HK-2]), secretome profile, and cellular senescence abundance. The direction of association between MSC function and patient characteristics were also tested. RNA-seq analysis identified 353 differentially expressed genes and downregulation of several immunomodulatory genes/pathways in DKD-MSC versus Control-MSC. DKD-MSC phenotype, differentiation, and tube formation capacity were preserved, but migration was reduced. DKD-MSC with and without interferon-gamma priming inhibited T-cell proliferation greater than Control-MSC. DKD-MSC medium contained higher levels of anti-inflammatory cytokines (indoleamine 2,3-deoxygenase 1 and prostaglandin-E2) and prorepair factors (hepatocyte growth factor and stromal cell-derived factor 1) but lower IL-6 versus control-MSC medium. DKD-MSC medium protected high glucose plus transforming growth factor-beta-exposed HK-2 cells by reducing apoptotic, fibrotic, and inflammatory marker expression. Few DKD-MSC functions were affected by patient characteristics, including age, sex, BMI, hemoglobin A(1c), kidney function, and urine albumin excretion. However, senescence-associated beta-galactosidase activity was lower in DKD-MSC from participants on metformin therapy. Therefore, while DKD altered the transcriptome and migratory function of culture-expanded MSCs, DKD-MSC functionality, trophic factor secretion, and immunomodulatory activities contributing to repair remained intact. These observations support testing of patient-derived MSC therapy and may inform preconditioning regimens in DKD clinical trials.